Instituto de Salud Carlos III (ISCIII)
Supporter
The Instituto de Salud Carlos III (ISCIII) is the main public research entity funding, managing and carrying out biomedical research in Spain. It is also the body responsible for managing the Health Research and Development Strategy within the framework of the National Plan of R&D.
Membership discount for your BMC & SpringerOpen article processing charges (APCs)
As an affiliated author, a membership discount is available on your APC.
Please follow the submission guidelines to benefit from this membership discount.
Instituto de Salud Carlos III (ISCIII)'s Articles
Page 1 of 23
-
Citation: Tropical Medicine and Health 2025 53:49
-
CAP1: a novel extracellular vesicle marker linked to endothelial senescence in atherosclerosis
Citation: Biology Direct 2025 20:46 -
Lipidomic analysis reveals metabolism alteration associated with subclinical carotid atherosclerosis in type 2 diabetes
Citation: Cardiovascular Diabetology 2025 24:152 -
Effects of urban airborne particulate matter exposure on the human upper respiratory tract microbiome: a systematic review
Citation: Respiratory Research 2025 26:118 -
Diagnosis of celiac disease on a gluten-free diet: a multicenter prospective quasi-experimental clinical study
Citation: BMC Medicine 2025 23:182 -
Wolbachia bacteria in Mansonella perstans isolates from patients infected in different geographical areas: a pilot study from the ESCMID Study Group for Clinical Parasitology
Citation: Parasites & Vectors 2025 18:97 -
Advanced serum lipoprotein and glycoprotein profiling for cardiovascular event prediction in type 2 diabetes mellitus: the LIPOCAT study
Citation: Cardiovascular Diabetology 2025 24:88 -
Unveiling the psychosocial impact of Elexacaftor/Tezacaftor/Ivacaftor therapy in Cystic Fibrosis patients
Citation: BMC Pulmonary Medicine 2025 25:81 -
Kidins220-deficient hydrocephalus mice exhibit altered glial phenotypes and AQP4 differential regulation in the retina and optic nerve, with preserved retinal ganglion cell survival
Citation: Fluids and Barriers of the CNS 2025 22:16 -
Triglyceride-independent associations between circulating levels of apolipoprotein C-III and biomarkers of inflammation
Citation: Cardiovascular Diabetology 2025 24:9 -
Diagnostic and prognostic implications of family history of fibrotic interstitial lung diseases
Citation: Respiratory Research 2024 25:433 -
Diagnostic performance of hepatitis C virus core antigen testing for detecting hepatitis C in people living with hepatitis B: a systematic review and meta-analysis
Citation: Infectious Diseases of Poverty 2024 13:89 -
How to present economic evaluations to non-technical audiences? Randomized trials with professionals and the general population
Citation: Archives of Public Health 2024 82:223 -
FAIR data management: a framework for fostering data literacy in biomedical sciences education
Citation: BMC Medical Research Methodology 2024 24:284 -
Occurrence and assemblage distribution of Giardia Duodenalis in symptomatic and asymptomatic patients in southeastern Iran (2019–2022)
Citation: Gut Pathogens 2024 16:68 -
Correction: Blastocystis occurrence and subtype diversity in European wild boar (Sus scrofa) from the Iberian Peninsula
Citation: Veterinary Research 2024 55:152 -
Approaching onchocerciasis elimination in Equatorial Guinea: Near zero transmission and public health implication
Citation: Infectious Diseases of Poverty 2024 13:86 -
Sitting less and moving more: the impact of physical activity on mortality in the population of Spain
Citation: BMC Public Health 2024 24:3140 -
Funding multinational investigator-initiated clinical studies in Europe: why and how?
Citation: Trials 2024 25:689 -
Blastocystis occurrence and subtype diversity in European wild boar (Sus scrofa) from the Iberian Peninsula
Citation: Veterinary Research 2024 55:133